polyclonal syrian hamster igg (Bio X Cell)
Bio X Cell is a verified supplier 
Bio X Cell manufactures this product 
94
Structured Review
Bio X Cell
polyclonal syrian hamster igg
Polyclonal Syrian Hamster Igg, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/syrian+hamster+igg/InVivoPlus+polyclonal+Syrian+hamster+IgG/bio_rxiv__64898__2026__02__02__703323-258-12-16
Average 94 stars, based on 23 article reviews
Polyclonal Syrian Hamster Igg, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/syrian+hamster+igg/InVivoPlus+polyclonal+Syrian+hamster+IgG/bio_rxiv__64898__2026__02__02__703323-258-12-16
Average 94 stars, based on 23 article reviews
polyclonal syrian hamster igg - by Bioz Stars,
2026-10
94/100 stars
Images
Related Articles
other:Article Title: Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models. Article Snippet: 3Phadke MS, et al. J Immunother Cancer 2025;13:e012011. doi:10.1136/jitc-2025-012011 X Cell) and Article Title: Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Article Snippet: INTRODUCTION: Sites of chronic tissue injury and inflammation demonstrate an increased propensity to develop cancers.. Tissue damage associated with chronic pancreatitis increases the risk of pancreatic ductal adenocarcinoma (PDAC).. Chronic pancreatitis can precede the development of PDAC or occur concurrently during cancer progression due to bile or pancreatic duct involvement. Article Title: Inhibitors of oncogenic Kras specifically prime CTLA4 blockade to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancer Article Snippet: Isotype treatments in this group received a combination of Control:Article Title: Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates Article Snippet: For checkpoint blockade immunotherapy experiments, anti-CTLA-4 (BioXcell, Clone 9H10) or anti-PD-1 (BioXcell, Clone 29F1.A12) were injected three times per week (first dose 200 μg, followed by 2 doses of 100 μg intraperitoneal injections) in a final volume of 100 μL diluted in PBS. .. The control mice received a Article Title: Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. Article Snippet: For checkpoint blockade immunotherapy experiments, anti-CTLA-4 (BioXcell, Clone 9H10) or anti-PD-1 (BioXcell, Clone 29F1.A12) were injected three times per week (first dose 200 μg, followed by 2 doses of 100 μg intraperitoneal injections) in a final volume of 100 μLdiluted in PBS. .. The controlmice received a Article Title: Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models Article Snippet: Mice received intraperitoneal doses of the following antibodies in a volume of 100 μL: anti-PD-1 antibody (200 μg; clone RMP1-14; cat. #BE0146; Bio X Cell) or anti-CTLA-4 (200 μg/; clone 9D9; cat. #BE0164; Bio X Cell) or anti-LAG-3 (200 μg; clone C9B7W; cat. #BE0174; Bio X Cell) or anti-TIM-3 (200 μg; clone RMT3-23; cat. #BE0115; Bio X Cell) as a doublet or triplet combination every 5 days. .. For isotype control, a cocktail of Article Title: Inducing mismatch repair deficiency sensitizes immune-cold neuroblastoma to anti-CTLA4 and generates broad anti-tumor immune memory Article Snippet: At day10, depending on the experiment, mice were given 250 mg of anti-PD1 antibody (clone RMP1-14, BioXCell), 200 mg of anti-CTLA4 antibody (clone 9H10, BioXCell) or a combination of both in 100 ml of PBS injected intraperitoneally (i.p.) every 3 days for a total of 3 injections on days 10, 13, and 16. .. Control mice received 250 mg of Article Title: KRAS G12D -Specific Targeting with Engineered Exosomes Reprograms the Immune Microenvironment to Enable Efficacy of Immune Checkpoint Therapy in PDAC Patients Article Snippet: For checkpoint blockade immunotherapy experiments, anti-CTLA-4 (BioXcell, Clone 9H10) or anti-PD-1 (BioXcell, Clone 29F1.A12) were injected three times per week (first dose 200 mg, followed by 2 doses of 100 mg intraperitoneal injections) in a final volume of 100 ml diluted in PBS. .. The control mice received a |